Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

MV0527 Aug. 23 at 9:18 PM

$CRVO

0 · Reply

MV0527 Aug. 23 at 9:14 PM

$CRVO

0 · Reply

RiddleSigma Aug. 23 at 10:19 AM

$CRVO CervoMed Inc is a clinical stage neurology company with development risks

1 · Reply

Doki0926 Aug. 23 at 8:48 AM

$CRVO it is impossible to be that kind of shit. 20 should be the absolute minimum

0 · Reply

Messerschmittbf109 Aug. 22 at 10:41 PM

$CRVO probably you right Garbage stock Garbage strategy

0 · Reply

BPler Aug. 22 at 8:07 PM

$CRVO Seeing instutional in reports entering with smaller stakes, I guess liquidity is an issue to buy at once so much without squeezing the price up. Thompson Davis also reporter yesterday that they bought in for like 14k shares https://fintel.io/de/i/thompson-davis

0 · Reply

Ghostofgreg1 Aug. 22 at 5:34 PM

$CRVO Ghabage Absolute Ghabage Unreal to think of all the time wasted here All the while Elder and clowns are laughing while counting their money Ghabage Total Ghabage

1 · Reply

Messerschmittbf109 Aug. 22 at 3:29 PM

$CRVO weird stock it seems only artificially pumped before news

0 · Reply

Enzo4u Aug. 22 at 1:56 PM

$CRVO All the pathetic PT's provided, have no idea where they are getting it from, maybe their a$$

1 · Reply

Enzo4u Aug. 22 at 1:55 PM

$CRVO think this is doomed

0 · Reply

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 26 days ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 6 weeks ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 3 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 5 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 5 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 5 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 5 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 7 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 9 months ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 9 months ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 9 months ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 9 months ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 9 months ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 9 months ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 10 months ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 10 months ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 7, 2024, 8:30 AM EST - 10 months ago

CervoMed to Participate in Upcoming Investor Conferences

Nov 4, 2024, 8:00 AM EST - 10 months ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 10 months ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 11 months ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 1 year ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 1 year ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Apr 3, 2023, 2:13 PM EDT - 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN

EXR

Mar 31, 2023, 8:01 PM EDT - 2 years ago

DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN

Mar 30, 2023, 7:00 AM EDT - 2 years ago

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Dec 16, 2022, 6:30 AM EST - 2 years ago

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

MV0527 Aug. 23 at 9:18 PM

$CRVO

0 · Reply

MV0527 Aug. 23 at 9:14 PM

$CRVO

0 · Reply

RiddleSigma Aug. 23 at 10:19 AM

$CRVO CervoMed Inc is a clinical stage neurology company with development risks

1 · Reply

Doki0926 Aug. 23 at 8:48 AM

$CRVO it is impossible to be that kind of shit. 20 should be the absolute minimum

0 · Reply

Messerschmittbf109 Aug. 22 at 10:41 PM

$CRVO probably you right Garbage stock Garbage strategy

0 · Reply

BPler Aug. 22 at 8:07 PM

0 · Reply

Ghostofgreg1 Aug. 22 at 5:34 PM

$CRVO Ghabage Absolute Ghabage Unreal to think of all the time wasted here All the while Elder and clowns are laughing while counting their money Ghabage Total Ghabage

1 · Reply

Messerschmittbf109 Aug. 22 at 3:29 PM

$CRVO weird stock it seems only artificially pumped before news

0 · Reply

Enzo4u Aug. 22 at 1:56 PM

$CRVO All the pathetic PT's provided, have no idea where they are getting it from, maybe their a$$

1 · Reply

Enzo4u Aug. 22 at 1:55 PM

$CRVO think this is doomed

0 · Reply

pinkal Aug. 22 at 4:27 AM

$CRVO if this falls below 7.1, look below for low 5s, very strong possibility

1 · Reply

nostic Aug. 21 at 3:07 PM

$CGTX $AVXL $CRVO $ANVS CGTX has run up a lot but it’s still so early and off people’s radar. It has about 3k watchers… those others? 9-23k. Catalysts likely coming and a nice dip here too. GLB 🚀

4 · Reply

5layer Aug. 21 at 1:29 PM

$CRVO

0 · Reply

kaizenj Aug. 20 at 8:53 PM

$CRVO looks like RA capital management didn’t sell out in Q2. Amended schedule 13G filing today, which corrects the form from 8/14/25 that showed 0 shares owned. https://ir.cervomed.com/static-files/67da37ec-c735-472c-af1a-90bbf249465a

2 · Reply

MV0527 Aug. 20 at 4:09 PM

$CRVO as painful as it is,....I'm long and strong. Last December it was under 2

0 · Reply

Enzo4u Aug. 20 at 3:26 PM

$CRVO what is wrong with this stock

1 · Reply

Messerschmittbf109 Aug. 20 at 1:59 PM

$CRVO Is there something wrong here or is someone taking advantage of this by knowing information in advance? All tp are double or thriple from now

1 · Reply

BPler Aug. 20 at 7:07 AM

$CRVO How we are pinned so hard down for months is insane. We had multiple breaksout just to get broken down within days sometimes in one day(!) Seeing more high profile institutional buying gives comfort with higher PTs, but still it movies strange for months now.

2 · Reply

MV0527 Aug. 19 at 11:57 PM

$CRVO This up and down is crazy. Makes no sense. Neflamapimod is a proven product. Hopefully a "smart "Big Pharma snatches them up beforeday traders have a chance to exploit it. This is definitely a drug that will succeed. Long CervoMed.

1 · Reply

Messerschmittbf109 Aug. 19 at 8:20 PM

$CRVO all house of affairs .. make trading Better they out of ba..lls

0 · Reply

BPler Aug. 19 at 5:40 PM

Morgan Stanley, Blackrock and Vanguard still holding $CRVO RA Capital is apparently already out, they had like 900k shares, this might be a reason for the downward trend the last weeks with the good news.

2 · Reply

Messerschmittbf109 Aug. 19 at 3:46 PM

$CRVO clearly they are playing with easy insider trading .. Our money is gone

1 · Reply

Market Cap	84.48M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	178,400
Avg Vol	418,550
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	15%
Beta	-0.79
Analysts	Strong Sell
Price Target	$21.50